SCPH
- scPharmaceuticals Inc.
()
Overview
Company Summary
scPharmaceuticals Inc. (SCPH) is a pharmaceutical company that focuses on developing and commercializing transformative pharmaceutical products for subcutaneous delivery. The company specializes in developing innovative treatments for heart failure, infectious diseases, and other serious conditions.
One of scPharmaceuticals' key areas of focus is heart failure, a chronic condition characterized by the heart's inability to pump blood effectively. The company has developed an innovative subcutaneous formulation of furosemide, a commonly used diuretic, called Furoscix. This product provides a convenient and effective alternative to traditional intravenous diuretics for the outpatient management of heart failure patients.
By administering Furoscix subcutaneously through a wearable infusion pump, patients can receive consistent and personalized doses of the medication in the comfort of their own homes. This allows for improved patient autonomy, reduced hospital admissions, and better management of fluid overload, a common complication of heart failure.
Apart from heart failure, scPharmaceuticals is also actively engaged in developing subcutaneous formulations for the treatment of infections such as antibiotics for acute bacterial skin and skin structure infections. These innovative subcutaneous therapies offer potential advantages over traditional oral or intravenous routes, such as increased convenience, improved bioavailability, and enhanced patient compliance.
Overall, scPharmaceuticals Inc. aims to provide advanced subcutaneous therapies that improve patient outcomes, enhance quality of life, and reduce the healthcare burden associated with hospitalization. By leveraging their expertise in subcutaneous drug delivery, the company aspires to bring novel and impactful treatments to patients in need.